title: Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females.
abstract: OBJECTIVE
  The purpose of this study was to assess the consequences of a national immunization program with HPV vaccine for both boys and girls in Denmark, including the prophylactic effects on all potentially vaccine preventable HPV-associated diseases in male and female.
  
  
  METHODS
  The study focussed on the quadrivalent vaccine which protects against HPV type 6, 11, 16 and 18, and the vaccine's protection against genital warts, cervical intraepithelial neoplasia, cervical cancer, anogenital cancer (anal, penile, vaginal and vulvar cancer) and head and neck cancer (oral cavity, oropharyngeal, hypopharyngeal and laryngeal cancer) were included in the analyses. In general, the analysis was performed in two phases. First, an agent-based transmission model that described the HPV transmission without and with HPV vaccination was applied. Second, an analysis of the incremental costs and effects was performed. The model did not include naturally-acquired immunity to HPV in the simulations.
  
  
  RESULTS
  In the base case result (i.e. vaccination of girls only, 85% vaccination rate, private market price at € 123 per dose ex. VAT) an ICER of 3583 €/QALY (3-dose regime) is estimated when all HPV-related diseases are taken into account. Vaccination of girls & boys vs. vaccination of girls only an ICER of 28,031 €/QALY (2-dose regime) and 41,636 €/QALY (3-dose regime) is estimated.
  
  
  CONCLUSIONS
  Extension of the current HPV programme in Denmark to include boys and girls is a cost effective preventive intervention that would lead to a faster prevention of cancers, cancer precursors and genital warts in men and women.
authors.affiliation: Centre for Applied Health Services Research and Technology Assessment (CAST), University of Southern Denmark, 5000 Odense C, Denmark ; Incentive, 2840 Holte, Denmark.
authors.forename: Jens
authors.initials: J
authors.lastname: Olsen
authors.affiliation: Sanofi Pasteur MSD ApS, 2800 Kgs, Lyngby, Denmark ; Medivir, 2800 Kgs, Lyngby, Denmark.
authors.forename: Tine Rikke
authors.initials: TR
authors.lastname: Jørgensen
keywords: Cancer; Cost-effectiveness; Gender neutral vaccination; Genital warts; HPV-related diseases; HPV-vaccination